UQSC2
/ University of Queensland, CEPI
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 25, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial.
(PubMed, J Infect Dis)
- P1 | "Cases of confirmed COVID-19 infection during the study were also examined...UQSC2 was equally well tolerated to the authorised comparator vaccine and produced an equally robust boost in neutralising immune response. These findings support the effectiveness of the MC2 platform in producing vaccines against newly emerging variants of SARS-CoV-2, and other respiratory viruses, as well as the platform's potential use in emergency response to novel viruses."
Journal • P1 data • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 06, 2024
A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.
(clinicaltrials.gov)
- P1 | N=70 | Completed | Sponsor: The University of Queensland | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 18, 2023
A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.
(clinicaltrials.gov)
- P1 | N=70 | Completed | Sponsor: The University of Queensland | Not yet recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Jun 2023 | Trial primary completion date: Mar 2024 ➔ Jun 2023
Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 20, 2023
A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.
(clinicaltrials.gov)
- P1 | N=70 | Not yet recruiting | Sponsor: The University of Queensland
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1